1. Coronavirus disease 2019 in adults with congenital heart disease: a position paper from the ESC working group of adult congenital heart disease, and the International Society for Adult Congenital Heart Disease.
- Author
-
Diller, Gerhard-Paul, Gatzoulis, Michael A, Broberg, Craig S, Aboulhosn, Jamil, Brida, Margarita, Schwerzmann, Markus, Chessa, Massimo, Kovacs, Adrienne H, and Roos-Hesselink, Jolien
- Subjects
COVID-19 pandemic ,SARS-CoV-2 ,RESPIRATORY infections ,CONGENITAL heart disease ,CARDIOVASCULAR diseases - Abstract
We are witnessing an unparalleled pandemic caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) associated with coronavirus disease 2019 (COVID-19). Current data show that SARS-CoV-2 results in mild flu-like symptoms in the majority of healthy and young patients affected. Nevertheless, the severity of COVID-19 respiratory syndrome and the risk of adverse or catastrophic outcomes are increased in patients with pre-existing cardiovascular disease. Patients with adult congenital heart disease (ACHD)—by definition—have underlying cardiovascular disease. Many patients with ACHD are also afflicted with residual haemodynamic lesions such as valve dysfunction, diminished ventricular function, arrhythmias or cyanosis, have extracardiac comorbidities, and face additional challenges regarding pregnancy. Currently, there are emerging data of the effect of COVID-19 on ACHD patients, but many aspects, especially risk stratification and treatment considerations, remain unclear. In this article, we aim to discuss the broad impact of COVID-19 on ACHD patients, focusing specifically on pathophysiology, risk stratification for work, self-isolation, hospitalization, impact on pregnancy, psychosocial health, and longer-term implications for the provision of ACHD care. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF